References
- Agarwal N, Sadhukhan P. Therapeutic Insights against Oxidative Stress Induced Diabetic Nephropathy: A Review. J Autoimmune Disord. 2015; 1: 1–17.
- Ahmad A, Mondello S, Di Paola R et al. Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: A comparison with n-acetylcysteine. Eur J Pharmacol. 2012; 674: 397–406.
- Ahmadi A, Mazooji N, Roozbeh J, Mazloom Z, Hasanzade J. Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients. Iran J Kidney Dis. 2013; 7: 461–467.
- Ahmadvand H. Effects of coenzyme Q10 on hemoglobin A1C, serum urea and creatinine in alloxan-induced Type 1 diabetic rats. Iran J Pharmacol Ther. 2012; 11: 64–67.
- Alam M, Rahman M. Mitochondrial dysfunction in obesity: Potential benefit and mechanism of co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord. 2014; 13: 1–11.
- Algenstaedt P, Schaefer C, Biermann T, et al. Microvascular Alterations in Diabetic Mice Correlate with Level of Hyperglycemia. Diabetes. 2003; 52: 542–549.
- Amin M, Asaad G, Abdel Salam R, El-Abhar H, Arbid M. Novel CoQ10 Antidiabetic Mechanisms Underlie Its Positive Effect: Modulation of Insulin and Adiponectine Receptors, Tyrosine Kinase, PI3K, Glucose Transporters, sRAGE and Visfatin in Insulin Resistant/Diabetic Rats. PLoS One. 2014; 9: e89169.
- Ammon HP, Muller PH, Eggstein M, Wintermantel C, Aigner B, Safayhi H, et al. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers. Arzneimittelforsch. 1992; 42: 642–645.
- Anwar M, Abd El-Moniem M, Megahed H, EL-Toukhy S, Mohammed N, Youness E. Effect of Coenzyme Q10 Supplementation on Markers of Oxidative Stress in Streptozotocin Induced Diabetic Rats. Journal of Applied Pharmaceutical Science. 2014; 4: 9–15.
- Ates O, Bilen H, Keles S, Alp H, Keles M, et al. Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy. Int J Ophthalmol. 2013; 6: 675–679.
- Badole SL, Bagul PP, Mahamuni SP et al. Oral L-glutamine increases active GLP-1 (7–36) amide secretion and improves glycemic control in streptozotocin-nicotinamide induced diabetic rats. ChemBiol Interact. 2013; 203: 530–541.
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–20.
- Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010; 1: 48–56.
- Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, et al. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol. 2011; 666: 135–141.
- Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009; 15: 1298–1306.
- Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotinamide induced rat model of type 2 diabetes. Acta Physiol Hung. 2014; 101: 408–420.
- Haber CA, Lam TK, Yu Z et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab. 2003; 285: E744–E753.
- Haraldsson B, Sörensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci. 2004; 19: 7–10.
- Hasegawa G, Yamamoto Y, Zhi J, Tanino Y, Yamasaki M, et al. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. Acta Diabetol. 2005; 42: 179–181.
- Ho E, Chen G, Bray TM. Supplementation of N-acetylcysteine inhibits NF-kappaB activation and protects against alloxan-induced diabetes in CD-1 mice. FASEB J. 1999; 13: 1845–1854.
- Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002; 56: 1137–1142.
- Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia. 2001; 44: 659–673.
- Jemai H, El Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. J Agric Food Chem. 2009; 57: 8798–8804.
- Kisic B, Miric D, Dragojevic I, Rasic J, Popovic L. Role of Myeloperoxidase in Patients with Chronic Kidney Disease. Oxid Med Cell Longev. 2016; 1–10.
- Kohei KA. Pathophysiology of type 2 diabetes and its treatment policy. JMAJ. 2010; 53: 41–46.
- Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes. 2019; 10: 1–15.
- Lee ES, Kim HM, Kang JS, Lee EY, et al. Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model. Nephrol Dial Transplant. 2016; 3: 391–400.
- Mahajan MS, Gulecha VS, Upaganlawar AB, Upasani CD. Antioxidant Defense in Diabetic Nephropathy In: Uddin S & Upaganlawar AB: Oxidative Stress and Antioxidant Defense: Biomedical value in Health and Diseases, 1st ed. New York: Nova; 2019.
- Maheshwari R, Balaraman R, Sen AK, Shukla D, Seth A. Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats. Renal Failure. 2017; 39: 130–139.
- Maheshwari RA, Balaraman R, Sen AK, Seth AK. Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats. Indian J Pharmacol. 2014; 46: 627–32.
- Maitra A. The Endocrine System. in: Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia: Elsevier Saunders; 2015.
- Masharani, U. Diabetes Mellitus and hypoglycemia. In: McPhee SJ, Papadakis MA, Tierney LM. Current medical diagnosis and treatment, 47th ed. New York: McGraw-Hill; 2008.
- Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga, M, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors. 2012; 38: 416–421.
- Midaoui A, Ismael M, Lu H, Fantus I, de Champlain J, Couture R. Comparative effects of N-acetyl-L-cysteineand ramipril on arterial hypertension, insulin resistance, andoxidative stress in chronically glucose-fed rats. Can J Physiol Pharmacol. 2008; 86: 752–60
- Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease. Origin and development of ideas. Diabetologia. 1999; 42: 263–285.
- Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983; 32: 64–78.
- Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, et al. Diabetic kidney disease: from physiology to therapeutics. J Physiol. 2014; 592: 3997–4012.
- Odetti P, Pesce C, Traverso N, Menini S, Maineri EP, et al. Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes. Diabetes. 2003; 52: 499–505.
- Oktem F, Ozguner F, Yilmaz HR, et al. Melatonin reduces urinary excretion of N-acetyl-beta–D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol. 2006; 33: 95–101.
- Pal PB, Sinha K, Sil PC. Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One. 2014; 9: e107220.
- Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004; 24: 333–344.
- Rajkumar L, Govindarajulu P. Increased degradation of dermal collagen in diabetic rats. Indian J Exp Bio. 1991; 29: 1081–1083.
- Rajkumar V, Ragatzki P, Sima A, Levy J. Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infaractions. Endocrine. 1999; 11: 57–60.
- Rosenfeldt FL, Haas SJ, Krum H. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21: 297–306.
- Rovira-Llopis S, Rocha M, Victor M et al. Is myeloperoxidase a key component in the ROS-induced vascular damage related to nephropathy in type 2 diabetes?” ARS. 2013; 19: 1452–1458.
- Roy S, Trudeau K, Roy S, Behl Y, Dhar S, Chronopoulos A. New insights into hyperglycemia-induced molecular changes in microvascular cells. J Dent Res. 2010; 89: 116–128.
- Schena FP and Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 16: 30–33.
- Shimizu MH, Coimbra TM, de Araujo M et al. N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int. 2005; 68: 2208–2217.
- Sourris K, Harcourt B, Tang P, Morley A, Huynh K, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med. 2012; 52: 716–723.
- Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992; 258: 1898–902.
- Teoh SL, Abdulatiff A, Das S. Histological changes in the kidneys of experimental diabetic rats fed with Momordicalcharantia (bitter gourd) extract. Rom J MorpholEmbryol. 2010; 51: 91–5.
- Vasavada N and Agarwal R. Role of Oxidative Stress in Diabetic Nephropathy. Adv Chronic Kidney Dis. 2005; 12: 146–154.
- Vora JP and Ibrahim HAA. Clinical manifestations and natural history of diabetic nephropathy. In: Johnson R and Feehally J: Comprehensive clinical nephrology, 2nd ed. Edinburgh: Mosby; 2003.
- Zhang X, Shi Z, Liu Q, Quan H, Cheng X. Effects of coenzyme Q10 intervention on diabetic kidney disease. Medicine. 2019; 98: 1–18.